Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

News [3583]

Initiative will test new drug combinations guided by tumour biology

Initiative will test new drug combinations guided by tumour biology

Researchers uncover potential novel therapeutic targets against natural killer/T-cell lymphoma

Researchers uncover potential novel therapeutic targets against natural killer/T-cell lymphoma

Pan-cancer T cell atlas reveals new details of tumour microenvironment

Pan-cancer T cell atlas reveals new details of tumour microenvironment

Blocking a key immune protein improves radiation therapy for cancer

Blocking a key immune protein improves radiation therapy for cancer

Blocking a key immune protein improves radiation therapy for cancer

Blocking a key immune protein improves radiation therapy for cancer

ASCO 2023: Adding pembrolizumab to chemotherapy improves survival in people with advanced cervical cancer

ASCO 2023: Adding pembrolizumab to chemotherapy improves survival in people with advanced cervical cancer 

ASCO 2023: Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumours

ASCO 2023: Safety & efficacy of the novel BRAF inhibitor FORE8394 in patients with advanced solid & CNS tumours

HER3: Survival pathway and therapeutic target in metastatic colorectal and pancreatic cancer

HER3: Survival pathway and therapeutic target in metastatic colorectal and pancreatic cancer

$FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma$

FDA grants accelerated approval to epcoritamab-bysp for relapsed or refractory diffuse large B-cell lymphoma and...

Preclinical candidate to target ENPP1 for cancer immunotherapy and the treatment of rare disease using generative AI

Preclinical candidate to target ENPP1 for cancer immunotherapy and the treatment of rare disease using generative...

More from ecancer